
	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CHIESI.001C1	APPLICATION NO. 10/672,504
	APPLICANT Plouvier et al.		
	FILING DATE September 26, 2003	GROUP 1646	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)	

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1	FR 3.533 M	03/64	France				X
	2	WO 99/47134	03/99	PCT (abstract in English)				
	3	WO 02/078676 A2	10/02	PCT (abstract in English)				
	4	FR 2.822.704	03/01	France (abstract in English)				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
<i>MS</i>	5	Cynober, Luc A., <u>The use of [alpha]-ketoglutarate salts in clinical nutrition and metabolic care</u> , <i>Current Opinion in Clinical Nutrition & Metabolic Care</i> , 2(1):33-37 (1999)
	6	Cynober, L., <u>Ornithine α-Ketoglutarate in Nutritional Support</u> , <i>Nutrition</i> 7(5):313-322 (1991)
	7	Brocker et al. <u>A Two-centre, Randomized, Double-blind Trial of Ornithine Oxoglutarate in 194 Elderly, Ambulatory, Convalescent Subjects, Age and Ageing</u> 23:303-306 (1994)
	8	Donati et al. <u>Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in seven burn patients</u> , <i>Clinical Nutrition</i> 18(5):307-311 (1999)
<i>MS</i>	9	Cynober et al. <u>Dénutrition - Signes cliniques et biologiques, traitement</u> , <i>La Revue Du Praticien</i> 50:1593-1599 (2000) (English translation not included)

S:\DOCS\MCB\MCB-2695.DOC
051104

EXAMINER <i>MS</i>	DATE CONSIDERED <i>10-7-2005</i>
*EXAMINER INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	